News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
225,866 Results
Type
Article (5016)
Company Profile (17)
Press Release (220833)
Section
Business (82215)
Career Advice (461)
Deals (15046)
Drug Delivery (8)
Drug Development (19085)
Employer Resources (30)
FDA (3677)
Job Trends (3901)
News (120142)
Policy (7504)
Tag
Academia (292)
Accelerated approval (2)
Adcomms (3)
Allergies (9)
Alliances (14785)
ALS (21)
Alzheimer's disease (247)
Antibody-drug conjugate (ADC) (12)
Approvals (3696)
Artificial intelligence (44)
Autoimmune disease (3)
Automation (3)
Bankruptcy (97)
Best Places to Work (2862)
Biosimilars (11)
Biotechnology (21)
Bladder cancer (10)
Brain cancer (7)
Breast cancer (48)
Cancer (464)
Cardiovascular disease (24)
Career advice (393)
Career pathing (3)
CAR-T (33)
Cell therapy (107)
Cervical cancer (2)
Clinical research (16074)
Collaboration (179)
Compensation (182)
Complete response letters (2)
COVID-19 (304)
CRISPR (8)
C-suite (114)
Cystic fibrosis (16)
Data (539)
Depression (7)
Diabetes (43)
Diagnostics (2046)
Digital health (3)
Diversity, equity & inclusion (12)
Drug discovery (15)
Drug pricing (6)
Drug shortages (1)
Duchenne muscular dystrophy (13)
Earnings (41119)
Editorial (2)
Employer branding (6)
Employer resources (31)
Events (37909)
Executive appointments (323)
FDA (4001)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (3)
Funding (191)
Gene editing (16)
Generative AI (2)
Gene therapy (53)
GLP-1 (111)
Government (413)
Guidances (76)
Healthcare (5037)
Huntington's disease (1)
IgA nephropathy (4)
Immunology and inflammation (15)
Indications (6)
Infectious disease (320)
Inflammatory bowel disease (24)
Inflation Reduction Act (2)
Influenza (3)
Intellectual property (15)
Interviews (53)
IPO (7832)
IRA (3)
Job creations (1121)
Job search strategy (360)
Kidney cancer (7)
Labor market (5)
Layoffs (100)
Leadership (5)
Legal (2332)
Liver cancer (18)
Lung cancer (54)
Lymphoma (33)
Management (10)
Manufacturing (54)
MASH (30)
Medical device (3863)
Medtech (3864)
Mergers & acquisitions (7430)
Metabolic disorders (127)
Multiple sclerosis (8)
NASH (6)
Neurodegenerative disease (11)
Neuropsychiatric disorders (1)
Neuroscience (347)
NextGen: Class of 2025 (1674)
Non-profit (727)
Now hiring (3)
Obesity (54)
Opinion (30)
Ovarian cancer (18)
Pain (14)
Pancreatic cancer (14)
Parkinson's disease (28)
Partnered (4)
Patents (22)
Patient recruitment (33)
Peanut (5)
People (24632)
Pharmaceutical (5)
Pharmacy benefit managers (2)
Phase I (4793)
Phase II (6980)
Phase III (5564)
Pipeline (664)
Policy (9)
Postmarket research (625)
Preclinical (1875)
Press Release (66)
Prostate cancer (27)
Psychedelics (3)
Radiopharmaceuticals (105)
Rare diseases (71)
Real estate (1874)
Recruiting (8)
Regulatory (5137)
Reports (14)
Research institute (301)
Resumes & cover letters (68)
Rett syndrome (4)
Schizophrenia (21)
Series A (28)
Series B (25)
Sickle cell disease (7)
Special edition (1)
Spinal muscular atrophy (28)
Sponsored (4)
Startups (1009)
Stomach cancer (1)
Supply chain (10)
Tariffs (5)
Vaccines (38)
Venture capitalists (2)
Weight loss (22)
Women's health (1)
Date
Today (30)
Last 7 days (356)
Last 30 days (921)
Last 365 days (9727)
2025 (3590)
2024 (11032)
2023 (13198)
2022 (18662)
2021 (19697)
2020 (18254)
2019 (13212)
2018 (10206)
2017 (10020)
2016 (9167)
2015 (12125)
2014 (9587)
2013 (7710)
2012 (8329)
2011 (8796)
2010 (8635)
Location
Africa (184)
Alabama (14)
Alaska (2)
Arizona (60)
Arkansas (1)
Asia (11478)
Australia (1613)
California (2091)
Canada (739)
China (75)
Colorado (85)
Connecticut (99)
Delaware (32)
Europe (24581)
Florida (303)
Georgia (34)
Idaho (23)
Illinois (117)
India (7)
Indiana (66)
Iowa (2)
Japan (78)
Kansas (24)
Kentucky (11)
Louisiana (5)
Maine (40)
Maryland (237)
Massachusetts (1669)
Michigan (87)
Minnesota (144)
Mississippi (1)
Missouri (23)
Montana (16)
Nebraska (12)
Nevada (26)
New Hampshire (16)
New Jersey (603)
New Mexico (5)
New York (496)
North Carolina (341)
North Dakota (3)
Northern California (1007)
Ohio (61)
Oklahoma (5)
Oregon (4)
Pennsylvania (365)
Puerto Rico (1)
Rhode Island (13)
South America (276)
South Carolina (7)
Southern California (756)
Tennessee (43)
Texas (243)
United States (7513)
Utah (65)
Virginia (48)
Washington D.C. (11)
Washington State (183)
West Virginia (2)
Wisconsin (26)
225,866 Results for "resverlogix corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Resverlogix Announces Updated Annual and Special Meeting of Shareholders
Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) announced today that its Annual and Special Meeting of Shareholders (the “Meeting”) will be held on Wednesday, July 31, 2024, commencing at approximately 1:00 pm (MT), as opposed to as previously scheduled for June 27, 2024.
May 28, 2024
·
3 min read
Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges
Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) announced today a two-year extension of the Company’s US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co.
May 13, 2024
·
3 min read
Resverlogix Announces Change to Its Board of Directors.
Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) today announced that Shawn Lu has stepped down from the Board of Directors
February 22, 2024
·
2 min read
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone’s Potential Therapeutic Benefits
Resverlogix Corp. (TSX: RVX) (“Resverlogix”, “the Company”) today announced publication of an article, entitled, “The BET inhibitor apabetalone decreases
January 11, 2024
·
6 min read
Business
Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders
Resverlogix Corp. (TSX: RVX) (“Resverlogix”, or the “Corporation”) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary, Alberta.
June 21, 2023
·
1 min read
Resverlogix Publishes on Apabetalone’s Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
Resverlogix Corp. (TSX: RVX) (“Resverlogix”) today announced the publication of a peer-reviewed article, entitled “Apabetalone, a Clinical-stage
October 4, 2023
·
5 min read
Resverlogix Announces Warrant Repricing and One-Year Extension
Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) announces that certain of its 27,461,157 common share purchase warrants
June 30, 2023
·
3 min read
Press Releases
Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
August 1, 2024
·
3 min read
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
Amsterdam, Netherlands and Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Resverlogix Corp. (TSX: RVX) (“Resverlogix”) (TSX:RVX) today announced that new guidelines published by the European Society of Cardiology
August 29, 2023
·
5 min read
Press Releases
Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges
July 16, 2024
·
3 min read
1 of 22,587
Next
